Dynavax Technologies reported $422.8M in Equity Capital and Reserves for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Equity Capital And Reserves Change
Adma Biologics ADMA:US $ 114.4M 12.53M
Agenus AGEN:US $ 3.42M 12.3M
Amgen AMGN:US $ 2419M 1503M
Astrazeneca AZN:US $ 35932M 408M
AstraZeneca AZN:LN 35932M 408M
Biogen BIIB:US $ 11872.5M 630.2M
Biomarin Pharmaceutical BMRN:US $ 4504.81M 113.49M
Bristol Myers Squibb BMY:US $ 32600M 1020M
Chimerix CMRX:US $ 27.93M 19.87M
Dynavax Technologies DVAX:US $ 422.8M 135.32M
Gilead Sciences GILD:US $ 20215M 288M
Glaxosmithkline GSK:US $ 16374M 193M
Idera Pharmaceuticals IDRA:US $ 21.13M 4.71M
Minerva Neurosciences NERV:US $ -8.38M 7.65M
Nektar Therapeutics NKTR:US $ 458.73M 149.16M
Neurocrine Biosciences NBIX:US $ 1423.4M 32.3M
Novartis NOVN:VX SF 62925M 1385M
Regeneron Pharmaceuticals REGN:US $ 20687.8M 773.1M
Sarepta Therapeutics SRPT:US $ 726.46M 130.43M
Tg Therapeutics TGTX:US $ 129.04M 41.35M
Vertex Pharmaceuticals VRTX:US $ 11933.5M 1026.5M